AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD

 AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD

AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study to Treat COPD

Shots:

  • The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] in 8,500+ patients with mod. to sev. COPD and a history of exacerbation(s) in the previous year, receiving at least two inhaled maintenance treatments at entry into the study
  • Results: 24% reduction in exacerbations; 46% reduction in the risk of all-cause mortality when compared with Bevespi Aerosphere, showed a 13% reduction in exacerbations compared with PT009. Additionally, demonstrated a reduction in the rate of mod. or sev. exacerbations at the half dose of budesonide
  • Breztri Aerosphere is an approved therapy in Japan and China for patients with COPD and is under regulatory review in the US and EU. As per the agreement to acquire Pearl Therapeutics, AstraZeneca will pay $150M as milestone upon US approval of the therapy for COPD

Click here to read full press release/ article | Ref: AstraZeneca | Image: Pharmaceutical Technology

Related News: AstraZeneca’s Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW’s Approval for Chronic Obstructive Pulmonary Disease in Japan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post